Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Innovent Biologics

DB:6IB
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6IB
DB
HK$45B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Innovent Biologics, Inc. operates as a development-stage biopharmaceutical company in China. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
6IB Share Price and Events
7 Day Returns
1.6%
DB:6IB
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
21.1%
DB:6IB
-7.4%
DE Biotechs
-14.2%
DE Market
6IB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innovent Biologics (6IB) 1.6% 9.9% 20.5% 21.1% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 6IB outperformed the Biotechs industry which returned -7.4% over the past year.
  • 6IB outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

6IB Value

 Is Innovent Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Innovent Biologics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Innovent Biologics.

DB:6IB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:6IB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 25%) (2.12%))
1.043
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.043 * 6.33%)
6.21%

Discounted Cash Flow Calculation for DB:6IB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Innovent Biologics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:6IB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 6.21%)
2020 -1,338.00 Analyst x3 -1,259.71
2021 -1,093.80 Analyst x5 -969.55
2022 262.67 Analyst x3 219.21
2023 1,005.50 Analyst x2 790.03
2024 1,371.50 Analyst x2 1,014.55
2025 1,641.31 Est @ 19.67% 1,143.10
2026 1,865.41 Est @ 13.65% 1,223.16
2027 2,041.52 Est @ 9.44% 1,260.31
2028 2,174.05 Est @ 6.49% 1,263.59
2029 2,270.29 Est @ 4.43% 1,242.33
Present value of next 10 years cash flows CN¥5,927.00
DB:6IB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥2,270.29 × (1 + -0.39%) ÷ (6.21% – -0.39%)
CN¥34,239.87
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥34,239.87 ÷ (1 + 6.21%)10
CN¥18,736.40
DB:6IB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥5,927.00 + CN¥18,736.40
CN¥24,663.40
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥24,663.40 / 1,342.44
CN¥18.37
DB:6IB Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:1801)
1.097
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥18.37 x 1.097
HK$20.16
Non-primary Listing Adjustment Factor 1 share in DB:6IB represents 0.11274x of SEHK:1801
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.11274x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 20.16 x 0.11274
€2.27
Value per share (EUR) From above. €2.27
Current discount Discount to share price of €3.76
= -1 x (€3.76 - €2.27) / €2.27
-65.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Innovent Biologics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innovent Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innovent Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6IB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥-1.46
SEHK:1801 Share Price ** SEHK (2020-04-08) in HKD HK$33.35
SEHK:1801 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥30.39
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innovent Biologics.

DB:6IB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:1801 Share Price ÷ EPS (both in CNY)

= 30.39 ÷ -1.46

-20.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovent Biologics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Innovent Biologics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Innovent Biologics's expected growth come at a high price?
Raw Data
DB:6IB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
64.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Innovent Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Innovent Biologics's assets?
Raw Data
DB:6IB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥3.95
SEHK:1801 Share Price * SEHK (2020-04-08) in HKD HK$33.35
SEHK:1801 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥30.39
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:6IB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:1801 Share Price ÷ Book Value per Share (both in CNY)

= 30.39 ÷ 3.95

7.69x

* Primary Listing of Innovent Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovent Biologics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Innovent Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Innovent Biologics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6IB Future Performance

 How is Innovent Biologics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
64.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innovent Biologics expected to grow at an attractive rate?
  • Innovent Biologics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Innovent Biologics's earnings growth is expected to exceed the Germany market average.
  • Innovent Biologics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6IB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6IB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 64.4%
DB:6IB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 33%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6IB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6IB Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 7,199 1
2023-12-31 7,450 555 1,195 2
2022-12-31 5,783 513 348 9
2021-12-31 3,780 -890 -692 12
2020-12-31 2,217 -1,069 -1,157 9
2020-04-09
DB:6IB Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 1,048 -1,720
2019-09-30 737 -4,125
2019-06-30 424 -1,596 -6,530
2019-03-31 253 -1,306 -6,151
2018-12-31 83 -1,016 -5,771
2018-09-30 75 -801 -3,041
2018-06-30 69 -587 -311
2018-03-31 72 -540 -437
2017-12-31 75 -492 -562

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Innovent Biologics's earnings are expected to grow significantly at over 20% yearly.
  • Innovent Biologics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6IB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Innovent Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6IB Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 0.90 0.90 0.90 1.00
2022-12-31 0.26 1.02 -0.52 5.00
2021-12-31 -0.48 0.21 -1.07 8.00
2020-12-31 -0.84 -0.40 -1.15 7.00
2020-04-09
DB:6IB Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 -1.46
2019-09-30 -4.09
2019-06-30 -7.79
2019-03-31 -10.49
2018-12-31 -17.24
2018-09-30 -13.27
2018-06-30 -2.52
2018-03-31 -4.01
2017-12-31 -5.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innovent Biologics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Innovent Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innovent Biologics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6IB Past Performance

  How has Innovent Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innovent Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innovent Biologics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Innovent Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Innovent Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Innovent Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innovent Biologics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6IB Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,047.53 -1,719.95 947.81 1,294.72
2019-09-30 736.51 -4,124.87 789.33 1,383.54
2019-06-30 423.68 -6,529.79 630.85 1,472.35
2019-03-31 253.13 -6,150.64 493.58 1,347.02
2018-12-31 82.59 -5,771.49 356.32 1,221.69
2018-09-30 74.75 -3,041.48 247.54 1,014.13
2018-06-30 68.74 -311.47 138.75 806.58
2018-03-31 71.85 -436.89 113.26 709.25
2017-12-31 74.96 -562.32 87.77 611.92
2016-12-31 28.77 -504.20 57.38 384.65

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Innovent Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Innovent Biologics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Innovent Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Innovent Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innovent Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6IB Health

 How is Innovent Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innovent Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innovent Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innovent Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Innovent Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innovent Biologics Company Filings, last reported 3 months ago.

DB:6IB Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4,756.13 825.00 4,846.79
2019-09-30 4,756.13 825.00 4,846.79
2019-06-30 3,528.52 802.00 3,624.16
2019-03-31 3,528.52 802.00 3,624.16
2018-12-31 4,194.41 792.00 4,597.66
2018-09-30 4,194.41 792.00 4,597.66
2018-06-30 -1,573.88 4,247.12 3,770.60
2018-03-31 -1,573.88 4,247.12 3,770.60
2017-12-31 -1,622.13 3,561.09 1,319.96
2016-12-31 -958.22 3,395.83 1,795.24
  • Innovent Biologics's level of debt (17.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Innovent Biologics's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Innovent Biologics's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Innovent Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innovent Biologics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6IB Dividends

 What is Innovent Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Innovent Biologics dividends. Estimated to be 0% next year.
If you bought €2,000 of Innovent Biologics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Innovent Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Innovent Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6IB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6IB Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 3.00
2021-12-31 0.00 5.00
2020-12-31 0.00 6.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Innovent Biologics has not reported any payouts.
  • Unable to verify if Innovent Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Innovent Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Innovent Biologics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Innovent Biologics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Innovent Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innovent Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innovent Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6IB Management

 What is the CEO of Innovent Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Yu
AGE 55
TENURE AS CEO 9.3 years
CEO Bio

Dr. De-Chao Yu, also known as Michael , Ph.D. is a Co-Founder of Innovent Biologics, Inc. and has been its Chairman, Chief Executive Officer and President since 2011. Dr. Yu has been Chairman of the board of directors and President at Cinda Biological Pharmaceutical (Suzhou) Co., Ltd. since August 2011. Dr. Yu has been Sichuan University doctoral tutor since September 2008. Dr. Yu was a Co-Founder, President and Chief Executive Officer of Chengdu Kanghong Biotech (Kanghong Biotech) since 2006 until 2011. Dr. Yu served as founding President and Chief Executive Officer of Kanghong Sagent Pharmaceuticals (now Sagent China) from 2006 to 2009. Prior to founding Kanghong Biotech and KSP, he served as Vice President of Research and Development at Applied Genetics (USA) and Calyon (USA). The latter was acquired by Cell Genesys (USA) in 2001, where he worked for three years following the acquisition. He is the Inventor of the world’s first oncolytic virus product, Oncorine (an oncology product) and China’s first novel antibody-like product, Conbercept (a drug for ocular diseases and oncology). From January 1997 to July 2001, he served as Vice president of new drug research and development at American Calydon biopharmaceutical company. From August 2001 to June 2005, he served as Chief Scientist at US Cell Genesys Biopharmaceuticals. From July 2005 to December 2005, he served as Vice president at USA Applied Genetics Biopharmaceutical Co. From January 2006 to March 2011, he served as General Manager at Chengdu Kang Hong Biological Technology Co., Ltd.; Vice president at Chengdu Kanghong Pharmaceutical Group. He serves as a Director of Shanghai Wu Meng Chao Cancer Medical Center Co., Ltd. He is Independent Director at PharmaBlock Sciences (Nanjing), Inc. From January 2006 to March 2011, he served as Director at Chengdu Kang Hong Biological Technology Co., Ltd. He was Director of Biological macromolecular protein drugs Sichuan Provincial Key Laboratory. He is also an Inventor of 61 issued patents and pending patents. He is a Professor at Sichuan University and a Guest Professor at Zhejiang University. Dr. Yu is a Member of Chinas 1000 Talents Program. Dr. Yu received his Doctorate Degree in Molecular Genetics from the Chinese Academy of Sciences and completed his Post-Doctoral Training at the University of California San Francisco (UCSF) where he worked for two further years.

CEO Compensation
  • Insufficient data for Michael to compare compensation growth.
  • Insufficient data for Michael to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Innovent Biologics management team in years:

1.8
Average Tenure
55
Average Age
  • The average tenure for the Innovent Biologics management team is less than 2 years, this suggests a new team.
Management Team

Michael Yu

TITLE
Chairman
AGE
55
TENURE
9.3 yrs

Ronald Ede

TITLE
Executive Director & CFO
AGE
60

Qinwei Zhou

TITLE
Chief Operating Officer
AGE
56

Vivian Zhang

TITLE
Chief People Officer
TENURE
0.8 yrs

Amy Que

TITLE
Senior Vice President

Wei Xu

TITLE
Senior Vice President

Min Liu

TITLE
Chief Commercial Officer

Yanju Wang

TITLE
Joint Company Secretary
AGE
30
TENURE
1.8 yrs

Lok Yee Chan

TITLE
Joint Company Secretary
AGE
28
TENURE
1.8 yrs

Linda Pullan

TITLE
Vice President of Business Development
Board of Directors

Ronald Ede

TITLE
Executive Director & CFO
AGE
60

Joyce Hsu

TITLE
Independent Non-Executive Director
AGE
44
TENURE
1.5 yrs

Michael Yu

TITLE
Chairman
AGE
55
TENURE
9.3 yrs

Frank McCormick

TITLE
Member of Scientific Advisory Board
AGE
69

Phil Rosenfeld

TITLE
Member of Scientific Advisory Board

Guanhua Du

TITLE
Member of Scientific Advisory Board
AGE
62

Xielong Luo

TITLE
Member of Scientific Advisory Board

Baoquan Zhu

TITLE
Member of Scientific Advisory Board
AGE
73

Charlie Cooney

TITLE
Independent Non-Executive Director
AGE
75

Nick Chen Chen

TITLE
Non-Executive Director
AGE
45
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Mar 20 Sell FIL Limited Company 12. Mar 20 12. Mar 20 -9,566,882 €3.60 €-34,416,456
16. Mar 20 Sell FMR LLC Company 11. Mar 20 11. Mar 20 -1,828,197 €4.04 €-7,378,253
10. Mar 20 Sell Invesco Ltd. Company 05. Mar 20 05. Mar 20 -12,282,000 €4.04 €-49,662,238
28. Feb 20 Sell Invesco Ltd. Company 25. Feb 20 25. Feb 20 -2,026,500 €4.12 €-8,353,719
25. Feb 20 Buy FMR LLC Company 20. Feb 20 20. Feb 20 15,147,000 €3.60 €54,458,819
25. Feb 20 Buy SDIC Innovation Investment Management Co., Ltd. Company 20. Feb 20 20. Feb 20 15,000,000 €3.60 €53,930,302
29. Jan 20 Sell Impresa Management LLC Company 22. Jan 20 22. Jan 20 -16,313,558 €3.57 €-58,196,245
04. Feb 20 Sell FIL Limited Company 30. Jan 20 30. Jan 20 -10,186,000 €3.50 €-35,668,287
20. Jan 20 Sell FIL Limited Company 15. Jan 20 15. Jan 20 -446,500 €3.58 €-1,600,476
16. Jan 20 Buy FIL Limited Company 13. Jan 20 13. Jan 20 12,083,500 €3.31 €39,980,637
14. Jan 20 Buy SDIC Innovation Investment Management Co., Ltd. Company 10. Jan 20 10. Jan 20 459,500 €3.25 €1,491,490
24. Dec 19 Buy FIL Limited Company 19. Dec 19 19. Dec 19 388,500 €3.08 €1,195,759
23. Dec 19 Sell FIL Limited Company 18. Dec 19 18. Dec 19 -1,612,065 €3.08 €-4,970,659
29. Nov 19 Buy FMR LLC Company 26. Nov 19 26. Nov 19 10,131,500 €3.37 €34,186,029
29. Nov 19 Sell FIL Limited Company 26. Nov 19 26. Nov 19 -10,479,000 €3.37 €-35,358,327
26. Nov 19 Sell Impresa Management LLC Company 21. Nov 19 21. Nov 19 -688,135 €3.14 €-2,162,488
25. Nov 19 Buy FIL Limited Company 20. Nov 19 20. Nov 19 10,282,352 €3.02 €31,048,159
23. Oct 19 Buy FIL Limited Company 18. Oct 19 18. Oct 19 18,500,000 €2.82 €52,095,827
09. Oct 19 Buy FIL Limited Company 03. Oct 19 03. Oct 19 1,337,500 €3.03 €4,050,446
04. Sep 19 Sell FIL Limited Company 30. Aug 19 30. Aug 19 -5,870,036 €2.94 €-17,261,343
20. Aug 19 Sell FIL Limited Company 15. Aug 19 15. Aug 19 -586,992 €2.64 €-1,550,603
14. Jun 19 Buy Invesco Ltd. Company 11. Jun 19 11. Jun 19 550,500 €3.00 €1,649,956
28. May 19 Sell FIL Limited Company 24. May 19 24. May 19 -10,620,000 €2.63 €-27,957,030
24. May 19 Sell FIL Limited Company 21. May 19 21. May 19 -17,129,497 €2.82 €-48,376,118
09. May 19 Buy OppenheimerFunds, Inc. Company 06. May 19 06. May 19 3,517,000 €2.73 €9,607,488
24. Apr 19 Sell Impresa Management LLC Company 17. Apr 19 17. Apr 19 -15,624,500 €2.96 €-46,265,958
24. Apr 19 Sell Lilly Asia Ventures Company 17. Apr 19 17. Apr 19 -14,600,000 €2.96 €-43,232,295
X
Management checks
We assess Innovent Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innovent Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6IB News

Simply Wall St News

6IB Company Info

Description

Innovent Biologics, Inc. operates as a development-stage biopharmaceutical company in China. The company develops a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, and autoimmune and metabolic diseases. Its principal drug candidates, including Tyvyt (sintilimab), anti-PD-1 monoclonal antibody for the treatment of gastric cancer, solid tumors, and esophageal carcinoma; IBI-301, a rituximab biosimilar for the treatment of chronic lymphocytic leukemia and rheumatoid arthritis; IBI-303, an adalimumab biosimilar for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and psoriasis; and IBI-305, a bevacizumab biosimilar for the treatment of oncology. The company has a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. Innovent Biologics, Inc. was founded in 2011 and is headquartered in Suzhou, China.

Details
Name: Innovent Biologics, Inc.
6IB
Exchange: DB
Founded: 2011
HK$5,310,912,132
1,342,443,210
Website: http://innoventbio.com
Address: Innovent Biologics, Inc.
168 Dongping Street,
Suzhou Industrial Park,
Suzhou,
Jiangsu Province, 215123,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 1801 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 31. Oct 2018
OTCPK IVBX.F Ordinary Shares Pink Sheets LLC US USD 31. Oct 2018
DB 6IB Ordinary Shares Deutsche Boerse AG DE EUR 31. Oct 2018
Number of employees
Current staff
Staff numbers
1,982
Innovent Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:39
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.